Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Current Assets (2021 - 2025)

Bioregenx (BRGX) has 5 years of Current Assets data on record, last reported at $273156.0 in Q3 2025.

  • For Q3 2025, Current Assets fell 26.38% year-over-year to $273156.0; the TTM value through Sep 2025 reached $273156.0, down 26.38%, while the annual FY2024 figure was $307796.0, 52.84% down from the prior year.
  • Current Assets reached $273156.0 in Q3 2025 per BRGX's latest filing, up from $249573.0 in the prior quarter.
  • Across five years, Current Assets topped out at $652664.0 in Q4 2023 and bottomed at $676.0 in Q4 2022.
  • Average Current Assets over 5 years is $271438.4, with a median of $294261.0 recorded in 2025.
  • Peak YoY movement for Current Assets: plummeted 97.22% in 2022, then soared 96447.93% in 2023.
  • A 5-year view of Current Assets shows it stood at $24358.0 in 2021, then tumbled by 97.22% to $676.0 in 2022, then skyrocketed by 96447.93% to $652664.0 in 2023, then plummeted by 52.84% to $307796.0 in 2024, then fell by 11.25% to $273156.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $273156.0 in Q3 2025, $249573.0 in Q2 2025, and $294261.0 in Q1 2025.